Eli Lilly Eyes Record Growth as GLP-1 Demand Reshapes Pharma Landscape

Analysts polled by FactSet project a significant leap in performance, with net income expected to reach $5.89 billion, up from $4.41 billion in the same period last year. Revenue is forecasted to climb to $17.94 billion, representing a nearly 33% increase year-over-year. Adjusted earnings are anticipated at $6.91 per share, reflecting the company’s ability to scale its high-margin metabolic treatments effectively.

The focus for investors remains the company's GLP-1 franchise, specifically Zepbound and Mounjaro. While demand for injectable treatments remains at record highs, Lilly is pivoting toward broader accessibility. Management is expected to provide updates on its direct-to-consumer platform and the long-term impact of recent price cuts on patient volume. The strategy aims to solidify market share before competitors can bridge the gap in the rapidly evolving obesity care sector.

Shifting Toward Oral Treatments and Acquisitions

Beyond its current blockbusters, Lilly is preparing the ground for orforglipron, an experimental oral weight-loss pill. Analysts suggest the convenience of a daily pill could outpace the demand for weekly injections, broadening the patient base to include those who are averse to needles. Investors are looking for a clear timeline for the drug's launch following anticipated FDA approval.

Strategic diversification also remains a priority for the Indianapolis-based firm. Last month, the company agreed to acquire Ventyx Biosciences for more than $1 billion, a move that integrates oral treatments for inflammatory diseases into its pipeline. On Wednesday, shareholders will be listening for how this acquisition fits into the broader 2024 growth strategy and whether Lilly will continue its aggressive M&A pace to bolster its non-metabolic portfolio.